March 28, 2024
Walgreens Takes $6 Billion Hit from VillageMD Investment Amid Strategic Review
Walgreens, VillageMD, Quarter 2, $6 billion loss, Write-down, Investment Value Decline, Strategic Review, Cost Savings Plan, Underperforming Clinics Closure
Gamida Cell Shares Plummet Following Transition to Privately Owned Entity Under Highbridge Capital Management
Gamida Cell, Share Crater, Private Transition, Highbridge Capital Management, Stem Cell Therapy Maker, Restructuring Support Agreement (RSA), Omisirge